The NASS Podcast

The NASS Podcast is a great way to consume education content on-the-go! The episodes offer in-depth discussions of a variety of topics in spine from key opinion leaders, including: 3D Printing; ACDF vs. Cervical Disc Replacement; Complications; Laminoplasty vs. ACDF; Neuromonitoring During Spine Surgery; Cellular-Based Allografts; Is Surgery for Axial Back Pain Still an Option?; Surgical Management of Degenerative Spondylolisthesis; SpineLine Author Discussions.

Navigating the Job Search for Spine Specialists

Featuring: Sandeep N. Gidvani, MD and Nickul Jain, MD Disclosures: Gidvani, Sandeep N.: Consulting: Xenco Medical (B), SeaSpine (None), Spinal Balance (None), SI-BONE (None), NuVasive (None).   Jain, Nickul: Consulting: Spineart (Future Compensation Expected); Research Support (Staff and/or materials): Globus Medical (Nonfinancial). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

06-16
07:28

Marketing Masquerading as Medical Information

Featuring: E. Kano Mayer, MD; Eeric Truumees, MD; Mark Cuccuzella, MD Disclosures: Cuccuzella, Mark: Nothing to Disclose. Mayer, E. Kano: Stock Ownership: Infinite Orthopedics (1%); Private Investments: Lanai Health Solutions (30%); Speaking and/or Teaching Arrangements: North America Spine Society (B); Trips/Travel: NASS (B).   Truumees, Eeric: Trips/Travel: AAOS (Travel Expense Reimbursement); Board of Directors: Seton Family of Doctors (Salary); Other Office: AAOS Communications Cabinet (E, Travel Expense Reimbursement, Editor-in-Chief of AAOS Now); Research Support - Staff and/or Materials: Relievant (B, Paid directly to institution/employer), Medtronic (A), Vertex Pharma (A), Dova Pharmaceuticals (A), Pfizer (B, Paid directly to institution/employer), Stryker Spine (B, Paid directly to institution/employer).   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

05-19
10:20

Preventing Blood Loss in Spine Surgery with Tranexamic Acid

Featuring: Moderator Alex Michael, MD and Author James Reynolds, MD James Reynolds, MD, co-chair of NASS' Patient Safety Committee, discusses Preventing Blood Loss in Spine Surgery with Tranexamic Acid. Reducing blood loss during spine surgery is one of the many responsibilities of spine surgeons to keep patients safe. Dr. Reynolds addresses this and more in the latest episode discussing an article that recently appeared in SpineLine. Access the article here.  Disclosures: Michael, Alex P: Nothing to Disclose   Reynolds, James B.: Nothing to Disclose   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

12-10
16:12

New Interventional Spine & Musculoskeletal Medicine Fellowships

Featuring: Moderator Renee Rosati, DO and Author David O'Brien, Jr., MD. NASS Treasurer David O'Brien, Jr., MD, discusses new Interventional Spine & Musculoskeletal Medicine Fellowships and the opportunities they will afford young physicians. Dr. O'Brien touches on NASS completing its inaugural ISMM fellowships with a 100% match, and more in this podcast with moderator Renee Rosati, DO. Access the SpineLine article here. Disclosures: O'Brien, David Reese: Nothing to Disclose   Rosati, Renee Michelle: Nothing to Disclose  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

10-27
24:35

Where Are We Headed with Endoscopic Spine Surgery

Featuring: Jin Sun Kim, MD and Michael Y. Wang, MD Disclosures: Kim, Jin Sun: Stock Ownership: Innovasive (1%); Consulting: Richard Wolf (Travel Expense Reimbursement), Elliquence (Travel Expense Reimbursement); Scientific Advisory Board: Innovasive (Nonfinancial); Grants: AOSpine (A). Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (1%), Medical Device Partners (1%); Consulting: Stryker (C), Spineology (C), K2M (C), DePuy Synthes (C); Scientific Advisory Board: Vallum (A).   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

09-22
08:59

How to Minimize the Burden of Fusion with ERAS

Featuring: Michael Y. Wang, MD and Daniel K. Resnick, MD Disclosures: Resnick, Daniel: Scientific Advisory Board: NIDUS (None). Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (1%), Medical Device Partners (1%); Consulting: Stryker (C), Spineology (C), K2M (C), DePuy Synthes (C); Scientific Advisory Board: Vallum (A). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

09-08
08:02

Stem Cell Therapies in the Treatment of Disc-Related Low Back Pain

Moderator Douglas Pahl, MD, interviews authors Alex Mierke, MD, and Omar Ramos, MD, about their article titled, "Stem Cell Therapies in the Treatment of Disc-Related Low Back Pain." Drs. Mierke and Ramos discuss what is already known about stem cell therapies and what still may lie ahead in this ever-changing medical landscape. Access the article here. Disclosures: Mierke, Alex : Nothing to Disclose   Pahl, Douglas W.: Consulting: Stryker (C, Outside 12-Month Requirement, Paid directly to institution/employer); Other: Orthofix (A, Outside 12-Month Requirement); Stock Ownership: Nanovis (14,837 Shares, Paid directly to institution/employer), Trainer Rx (less than 1%), Vertera (D, Paid directly to institution/employer); Trips/Travel: Astrazeneca (A, Outside 12-Month Requirement), Boston Scientific (B, Outside 12-Month Requirement), DePuy/Synthes (A, Outside 12-Month Requirement), DJO (A, Outside 12-Month Requirement), Globus (A, Outside 12-Month Requirement), Horizon (A, Outside 12-Month Requirement), Medtronic (A, Outside 12-Month Requirement), Stryker (B, Outside 12-Month Requirement), Zimmer/Biomet (C, Outside 12-Month Requirement). Ramos, Omar: Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

09-01
28:46

Considerations for Spinal Fusion Surgery in the Elderly: Osteoporosis, Sarcopenia & Frailty

Featuring: Joseph S. Butler, PhD, FRCS and Arjun S. Sebastian, MD Disclosures: Butler, Joseph S.: Nothing to Disclose (Sep 26, 2019).   Sebastian, Arjun S.: Nothing to Disclose (Feb 04, 2019) Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

08-25
07:05

ALIF: Stand Alone and When to Back Up

Featuring: Mark M. Mikhael, MD; Deepak Reddy, MD; Bradley Saitta, MD; Nick Shamie, MD Disclosures: Mikhael, Mark M.: Consulting: Clariance Spine (B), GS Medical (B). Reddy, Deepak: Nothing to Disclose. Saitta, Bradley: Nothing to Disclose. Shamie, Nick: Royalties: Seaspine (B); Stock Ownership: SI Bone (100000 Shares, 1%), Vertiflex (200000 Shares, 1%); Consulting: Stryker (Financial, 0), Seaspine (Financial, 0), SI Bone (Financial, 0), Vertiflex (Financial, 0); Speaking and/or Teaching Arrangements: Medtronic (Financial, 0); Trips/Travel: Medtronic (Financial, 0); Board of Directors: Vertiflex (Financial, Medical Director); Scientific Advisory Board: SI Bone (Financial, Medical Advisory Board). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

08-11
08:38

Use of Mesenchymal Cellular Bone Matrix in Complex Cervical Surgery

Featuring: Mark M. Mikhael, MD; Deepak Reddy, MD; Bradley Saitta, MD; Nick Shamie, MD Disclosures: Mikhael, Mark M.: Consulting: Clariance Spine (B), GS Medical (B).  Reddy, Deepak: Nothing to Disclose.   Saitta, Bradley: Nothing to Disclose. Shamie, Nick: Royalties: Seaspine (B); Stock Ownership: SI Bone (100000 Shares, 1%), Vertiflex (200000 Shares, 1%); Consulting: Stryker (Financial, 0), Seaspine (Financial, 0), SI Bone (Financial, 0), Vertiflex (Financial, 0); Speaking and/or Teaching Arrangements: Medtronic (Financial, 0); Trips/Travel: Medtronic (Financial, 0); Board of Directors: Vertiflex (Financial, Medical Director); Scientific Advisory Board: SI Bone (Financial, Medical Advisory Board).   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

07-28
08:59

Graft Selection for Interbody Fusion

Featuring: Zoher Ghogawala, MD; Han Jo Kim, MD; Khoi D. Than, MD Disclosures: Ghogawala, Zoher: Board of Directors: Cervical Spine Research Society (Research Committee Chair, Registry Director), GN2.0-Nidus (66%), Joint Spine Section - AANS-CNS (Chair).   Kim, Han Jo: Board of Directors: AOSpine (B); Fellowship Support: AOSpine (D, Paid directly to institution/employer); Research Support (Staff and/or materials): CSRS (C, Outside 12-Month Requirement, Paid directly to institution/employer), ISSGF (C, Paid directly to institution/employer); Royalties: K2M (D), Zimmer Biomet (F).   Than, Khoi D.: Consulting: Bioventus (B), Medtronic (A). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

07-14
10:05

Spinal Masqueraders

Featuring: Evan K. Johnson, PT, DPT, OCS and Rick J. Placide, MD, PT Disclosures: Johnson, Evan K. : Nothing to Disclose.   Placide, Rick J. : Nothing to Disclose. Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

06-30
09:32

How to Choose Between Posterior Interbody Fusions Versus Lateral Interbody Fusion

Featuring: Sandeep N. Gidvani, MD and Paul R. Gause, MD Disclosures: Gause, Paul R. : Speaking and/or Teaching Arrangements: Medtronic (C).  Gidvani, Sandeep N. : Consulting: Xenco Medical (B), SeaSpine (None), Spinal Balance (None), SI-BONE (None), NuVasive (None).   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

06-02
08:07

Stem Cells and Degenerative Disc Disease

Featuring: Zorica Buser, PhD and Mark Erwin, DC, PhD Disclosures: Buser, Zorica: Consulting: AOSpine (B, Outside 12-Month Requirement), Xenco Medical (B, Outside 12-Month Requirement); Research Support (Investigator Salary): SeaSpine (F, Paid directly to institution/employer); Research Support (Staff and/or materials): Next Science (F, Paid directly to institution/employer), SeaSpine (F, Paid directly to institution/employer); Trips/Travel: AO Spine (Travel reimbursements for AO Spine Knowledge forum meetings and congresses).   Erwin, Mark: Board of Directors: Notogen (Stock Ownership disclosed); Grants: Skoll Family Trust (G,Paid directly to institution/employer); Research Support (Investigator Salary): Canadian Chiropractic Research Foundation (D); Research Support (Staff and/or materials): Skoll Family Trust (F, Paid directly to institution/employer); Scientific Advisory Board: Notogen (Stock Ownership dislcosed); Stock Ownership (including options, warrants): Notogen Inc (33%). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

05-05
08:01

Use of Bone Cement in Metastatic Spinal Disease and Beyond

Featuring: Matthew L. Goodwin, MD, PHD (Washington University), Dan Sciubba, MD (Johns Hopkins), and Joe Schwab, MD, MS (Harvard/Massachusetts General Hospital) Use of bone cement in the spine has been marred by early controversy, including debate over kyphoplasty/vertebroplasty and whether use of bone cement in spine surgery was safe or effective.  Now with recent publications reviewing almost 20 years of cement use in the spine, the data are relatively convincing that bone cement in spine surgery is not only useful, but also relatively safe.   In this podcast, these spine tumor surgeons from NASS' Section on Spine Oncology discuss the history of bone cement in the spine, the current use/indications for cement (e.g. metastatic spinal disease, osteoporosis), current techniques (e.g. through fenestrated pedicle screws), and discuss potential complications as well as practical tips for employing these techniques. Disclosures: Goodwin, Matthew L.: Consulting: Augmedics (A); Fellowship Support: AO Spine  (Salary, Fellowship Support), NREF (Salary, Fellowship Support); Royalties: Kendall Hunt (B); Stock Ownership: ROM3 (200 Shares, Outside 12-Month Requirement). Sciubba, Daniel M.: Consulting: Baxter (B), DePuy-Synthes (B), Globus (B), Medtronic (C), Nuvasive (B), Stryker (C). Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (Nonfinancial); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement), Stryker Spine (B, Outside 12-Month Requirement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

04-28
17:28

Identifying and Managing Physician Burnout in Today’s Health Care Environment

Did you know that physicians, as a group, have lower work-life satisfaction compared to the general population? The consequences of burnout are borne both by the individual physician and the health care system. The recognition of burnout as a serious individual and institutional challenge is leading to an increased need to design, implement, and evaluate systems that promote well-being. Moderator Richard L. Skolasky, Jr., Sc.D. interviews Todd Albert, MD and Eric Muehlbauer, MJ, CAE on this very important topic to assist the listener in ultimately being able to identify and strategize to mitigate risk factors in their own lives or in the organization that they represent. Disclosures: Albert, Todd J.: Board of Directors: American Orthopaedic Association (Nonfinancial, Treasurer-Elect), Hospital For Special Surgery (None, Surgeon-in-Chief Emeritus and Medical Director), Scoliosis Research Society (Nonfinancial, Past President); Consulting: Nuvasive (B); Other: JP Medical Publishers (B), Saunders/Mosby- Elsevier (B), Springer (A), Thieme Medical Publishers (B); Research Support (Staff and/or materials): PCORI (D); Royalties: DePuy Synthes Spine (F); Stock Ownership: ASIP (D), Augmedics (F), Biomerix (D, 42,253 Shares), Bonovo Orthopedics (D, 85,737 Shares), Crosstrees Medical  (D,  <1%), Cytodyn Inc. (F), Gentis (D), Innovative Surgical Designs (F), InVivo Therapeutics (C, <1%. Advisory Board, Stock options.), Invuity  (C, <1%. Member of Advisory Board, stock options.), Morphogenesis (E), Paradigm Spine, LLC (F, <1%.), Physician Recommended Nutriceuticals (D), PMIG (D), Pulse Equity (F), Spinicity  (D, <1%.), Strathspey Crown (F), Surg.IO (E), Vital 5 (None, <1%. Advisory Board, Stock Holder), Zimmer Biomet  (F). Muehlbauer, Eric J.: Nothing to Disclose   Skolasky, Richard L.: Board of Directors: North American Spine Society (Nonfinancial, Governance Committee, Chair Research Program Management, Chair Board of Directors, voting member); Other: International Society For Quality Of Life Research (Nonfinancial, Associate Editor for Quality of Life Research). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

04-14
24:07

Optimizing the High Risk Patient for Surgery and Burnout

Featuring: F. Todd Wetzel, MD; Carrie A. Diulus, MD; Mark Cuccuzella, MD Disclosures: Cuccuzella, Mark : Nothing to Disclose Diulus, Carrie A. : Trips/Travel: NASS (Travel Expense Reimbursement).   Wetzel, F. Todd : Stock Ownership: Relievant Medical (1%).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

03-31
13:09

Spinal Cord Mapping

Featuring: Lawrence G. Lenke, MD; Evan K. Johnson, PT, DPT, OCS; Neel Anand, MD Disclosures: Anand, Neel: Royalties: Medtronic (F), Nuvasive (B), Globus Medical (B), Elsevier (B); Stock Ownership: Globus (, unknown), Medtronics (, unknown); Private Investments: Paradigm Spine (, 1%, unknown), Bonovo Orthopaedics (, 1%, unknown), Pearl Diver (, 1%, unknown), Theracell (, 1%, unknown), GYS Tech (, 1%, unknown); Consulting: Spinal solutions (Financial, Stock options : Unknown ); Speaking and/or Teaching Arrangements: Medtronic (Financial, 42000); Trips/Travel: Medtronic (Financial, Included with consulting fees); Scientific Advisory Board: Globus Medical (Financial, 0). Johnson, Evan K. : Nothing to Disclose. Lenke, Lawrence G.: Consulting: DePuy Synthes (D, Outside 12-Month Requirement), K2M (D, Outside 12-Month Requirement), Medtronic (I, Outside 12-Month Requirement, Paid directly to institution/employer); Device or Biologic Distribution Group (Physician-Owned Distributorship): Medtronic (I), Quality Medical Publishing  (A); Grants: Fox Family Foundation (A); Other: AOSpine (D, Paid directly to institution/employer), Broadwater (B), Scoliosis Research Society (B), The Spinal Research Foundation (Travel Expense Reimbursement); Research Support (Staff and/or materials): EOS Imaging (A), Setting Scoliosis Straight Foundation (A).     Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

03-24
10:58

Augmented Reality, Virtual Reality and Artificial Intelligence: Are We There Yet?

Moderator Douglas Pahl, MD interviews Karthik Madhavan, MD about a SpineLine articled he helped author titled, "Augmented Reality, Virtual Reality and Artificial Intelligence: Are We There Yet?". Dr. Madhavan talks about the exciting developments with augmented reality and how there is still much to learn in the cutting-edge technology. This article first appeared in the January/February 2020 edition of SpineLine. Access the article here.  Disclosures: Madhavan, Karthik : Nothing to Disclose   Pahl, Douglas W.: Consulting: Stryker (C, Outside 12-Month Requirement, Paid directly to institution/employer); Other: Orthofix (A, Outside 12-Month Requirement); Stock Ownership: Nanovis (14,837 Shares, Paid directly to institution/employer), Trainer Rx (<1%), Vertera (D, Paid directly to institution/employer); Trips/Travel: Astrazeneca (A, Outside 12-Month Requirement), Boston Scientific (B, Outside 12-Month Requirement), DePuy/Synthes (A, Outside 12-Month Requirement), DJO (A, Outside 12-Month Requirement), Globus (A, Outside 12-Month Requirement), Horizon (A, Outside 12-Month Requirement), Medtronic (A, Outside 12-Month Requirement), Stryker (B, Outside 12-Month Requirement), Zimmer/Biomet (C, Outside 12-Month Requirement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5

03-17
30:27

Epidural Abscess

Featuring: Joseph H. Schwab, MD; Andrew J. Schoenfeld, MD Disclosures: Schoenfeld, Andrew J.: Royalties: Wolters Kluwer, Springer (B); Consulting: ArborMetrix (C); Trips/Travel: JBJS (A); Other Office: Journal of Bone and Joint Surgery (C); Research Support - Staff and/or Materials: CMS (D, Paid directly to institution/employer); Grants: Department of Defense (D, Paid directly to institution/employer), OREF (D, Paid directly to institution/employer), NIH (F, Paid directly to institution/employer).   Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (Nonfinancial); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement), Stryker Spine (B, Outside 12-Month Requirement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

03-10
07:37

Recommend Channels